Are there any pending pharmacokinetic studies of antiretroviral drugs in the elderly?
Philippe Morlat, MD, PhD: Not really. The main problem in elderly patients is polypharmacy, because they take many drugs against many comorbidities. There are a lot of trials which study the interactions between antiretroviral drugs and other medications that are taken by these people, but there are no pharmacokinetic studies which are predicted.